Index | MSCI World Health Care ESG Reduced Carbon Select 20 35 Capped |
Investment focus | Equity, World, Health Care, Social/Environmental |
Fund size | GBP 102 m |
Total expense ratio | 0.18% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Yes |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 11.72% |
Inception/ Listing Date | 3 November 2021 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
Revision Company | Deloitte |
Fiscal Year End | 30 November |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Germany | Unknown |
Switzerland | Unknown |
Austria | Unknown |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Novo Nordisk A/S | 6.44% |
Eli Lilly & Co. | 5.31% |
Novartis AG | 4.79% |
Amgen, Inc. | 4.12% |
Gilead Sciences, Inc. | 3.57% |
Elevance Health, Inc. | 3.44% |
Vertex Pharmaceuticals, Inc. | 3.42% |
The Cigna Group | 3.27% |
Zoetis | 3.26% |
Alcon AG | 2.72% |
Health Care | 91.81% |
Consumer Discretionary | 0.22% |
Other | 7.97% |
YTD | -1.73% |
1 month | -4.80% |
3 months | -8.53% |
6 months | -6.15% |
1 year | +2.58% |
3 years | +8.17% |
5 years | - |
Since inception (MAX) | +8.77% |
2023 | -1.70% |
2022 | +8.16% |
2021 | - |
2020 | - |
Volatility 1 year | 11.72% |
Volatility 3 years | 14.55% |
Volatility 5 years | - |
Return per risk 1 year | 0.22 |
Return per risk 3 years | 0.18 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -9.15% |
Maximum drawdown 3 years | -13.75% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -13.75% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
Euronext Amsterdam | EUR | WHCA | WHCA NA | ||
London Stock Exchange | GBP | WHCA |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 989 | 0.40% p.a. | Accumulating | Sampling |
iShares Ageing Population UCITS ETF | 378 | 0.40% p.a. | Accumulating | Sampling |
Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 130 | 0.35% p.a. | Accumulating | Full replication |
Invesco S&P World Health Care ESG UCITS ETF Acc | 62 | 0.18% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |